HC Wainwright Reaffirms “Buy” Rating for NRx Pharmaceuticals (NASDAQ:NRXP)

NRx Pharmaceuticals (NASDAQ:NRXP)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a note issued to investors on Monday,Benzinga reports. They currently have a $19.00 price target on the stock.

Several other equities analysts have also issued reports on the stock. Ascendiant Capital Markets boosted their target price on shares of NRx Pharmaceuticals from $43.00 to $44.00 and gave the company a “buy” rating in a report on Thursday, September 12th. EF Hutton Acquisition Co. I raised shares of NRx Pharmaceuticals to a “strong-buy” rating in a research note on Monday, October 21st.

NRx Pharmaceuticals Price Performance

Shares of NRx Pharmaceuticals stock opened at $1.27 on Monday. NRx Pharmaceuticals has a fifty-two week low of $1.10 and a fifty-two week high of $7.33. The firm has a market capitalization of $15.35 million, a P/E ratio of -0.59 and a beta of 1.27. The company’s 50 day moving average price is $1.39 and its two-hundred day moving average price is $2.15.

Institutional Investors Weigh In On NRx Pharmaceuticals

A hedge fund recently bought a new stake in NRx Pharmaceuticals stock. Anson Funds Management LP bought a new position in shares of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 142,525 shares of the company’s stock, valued at approximately $241,000. Anson Funds Management LP owned approximately 1.33% of NRx Pharmaceuticals at the end of the most recent reporting period. Hedge funds and other institutional investors own 4.27% of the company’s stock.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.